Abstract The purpose of this study is to investigate the effects of Lang-du extract (LDE) from Traditional Chinese Medicine (TCM) Euphorbia fischeriana Steud on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action. Our present results have shown that LDE significantly suppressed the in vitro melanoma cell growth in doseand time-dependent manners. LDE also displayed the synergistic effect with c-radiation on the reduction of the cell viability in melanoma cells. The animal experimental results further confirmed that compared with the control group without drug treatment, the tumor volume in mice was significantly and timedependently less in LDE group. The absolute weight of solid tumor in the LDE group was 7-fold lower than that in the control group. Western blot analysis indicated that LDE markedly down-regulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein Bax, eventually leading the reduction of Bcl-2/Bax protein ratios both in the cultured melanoma cells and in the tumors from melanoma-bearing mice. In addition, LDE significantly reduced the tumor progressionassociated protein levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor/ scatter factor (HGF/SF), and osteopontin (OPN) in tumors from the LDE-treated mice. Our findings suggest that LDE may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of melanoma and other cancer. 
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Introduction
Although melanoma accounts for only four percent of all dermatologic cancers, it is responsible for 80 percent of deaths from skin cancer (Miller and Mihm 2006) ; metastatic stage melanoma is an aggressive disease that few patients survive for [2 years. Compounding this, scores of clinical trials testing different adjuvant therapies have brought no significant improvement in the survival outlook for these patients (Sasse et al. 2007 ). To find novel natural compounds with low toxicity and high selectivity of killing various cancer cells including melanoma cells is an important area in cancer research. Due to their wide range of biological activities and low toxicity in animal models, some natural products have been used as alternative treatments for cancer. Lang-du (LD) is a naturally occurring product from Traditional Chinese Medicine (TCM) Euphorbia fischeriana Steud. In China, LD has been used to treat clinical patients with cancer, edema, and ascites for many years . Chemical investigation of this plant revealed that it mainly contained diterpenoids, triterpenoids, and steroids (Qin and Xu 1998) . Some of these compounds in the LD have shown inhibitory effects on the in vitro growth of human leukemia K562 (Luo and Wang 2006) , hepatoma HepG2 (Yan et al. 2008; Wang et al. 2009a, b) and human prostate LNCaP cancer cell line (Liu et al. 2002) . However, whether or not the extract from LD has inhibitory activities against melanoma growth in animal is unclear. In this study, we investigated the in vitro and in vivo effects of LD extract (LDE) on the growth of melanoma cells and its molecular mechanisms of action. We show that the LDE significantly reduced the viability of melanoma cells by inducing apoptosis and regulating the expressions of Bcl-2 and Bax proteins in dose-dependent manners. More importantly, the LDE significantly suppressed the tumor growth in melanoma-bearing mice and reduced the ratio of Bcl-2/Bax and the levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), and osteopontin (OPN) in tumors.
Materials and methods
Materials
RPMI 1640 medium, penicillin, streptomycin, fetal bovine serum (FBS), 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), trypan blue dye, trypsin/EDTA, and all other chemicals employed in this study were purchased from Sigma Chemical Co. (St. Louis, MO). Antibodies against Bcl-2, Bax, and b-actin were purchased from Cell Signaling Technology, Inc. (Beverley, MA). Acrylamide and the protein assay kits were obtained from Bio-Rad (Hercules, CA).
Preparation for Lang-du extract
The roots of E. fischeriana Steud were purchased from Lunan Pharmaceuticals in Linyi, Shandong Province, China. The powdered roots of E. fischeriana Steud were extracted with 88% ethanol at 50°C under mixing. After precipitation, the cooled solution was filtered and evaporated under reduced pressure to give a residue. Then, the extract was suspended in distilled water. After precipitation with water once more, the supernatant was condensed as a Lang-du extract (LDE) for the in vitro and in vivo experiments. There are about 0.53% of jolkinolide (A, B), 1.06% of fischeriana (A, B) and 1.75% of flavonoid in LDE.
Cell culture and in vitro growth assays
The murine melanoma cell line B16 (B16M) was obtained from the American Type Culture Collection. The B16M cell line was incubated in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS), glutamine (2 mM), penicillin (100 U/ mL) and streptomycin (100 lg/mL) at 37°C in a humidified incubator with 95% air/5% CO 2 atmosphere. The in vitro assays were done according to our published methods Huang et al. 2009; Zhang et al. 2000) . The cells were cultured in RPMI 1640 medium supplemented with 10% FBS containing different concentrations of LDE. The cells in control group were treated with PBS vehicle. For detection of the effect of LDE on the in vitro growth of B16M cells, the relative cell viability was measured 24, 48, and 72 h after the treatments using MTT growth assay kit. For detection of the effect of LDE on the in vitro growth in c-radiation-treated B16M cells, the cells were treated with c-radiation at dose of 8 Gy in the absence or presence of LDE at 0.4 mg/mL. After the treated cells were cultured for 48 h, the relative cell viability was determined using a trypan blue dye exclusion assay as described previously (Zhang et al. 2000) . Each experiment was repeated three times.
Morphological evaluation of apoptotic cells
This was done according to our published methods (Zhang et al. 2000) . In brief, B16M cells at 70% confluence were, respectively treated for 48 h with LDE at concentrations of 0 (PBS vehicle as control), 0.4, and 1.2 mg/mL. The treated cells were fixed with 1% glutaraldehyde in PBS for 30 min at room temperature, washed in PBS, and stained with 1 mM Hoechst 33258 for 30 min at room temperature. The morphological changes in the nuclear chromatin were observed under a fluorescent microscope (Nikon, TE2000-U, Japan), using a 409 lens.
Animal experimentation
Female C57BL/6 J mice, 5 weeks old (from SLRC Laboratory Animal, Chinese Academy of Sciences, Shanghai, China) were given a standard laboratory diet (from the SLRC Laboratory Animal) and distilled water. The diet and water were available ad libitum. The mice were deprived of their diet at 9:00 a.m. on the day of killing, but allowed free access to water until killing, which was performed 4 h later. The mice were kept on a 12-h light/dark cycle at 22 ± 2°C and allowed to adjust to their environment for 1 week before the initiation of experiments. The mice were injected s.c. in the left flank with 2 9 10 5 B16M cells in 100 lL serum-free medium. Two groups of mice (eight mice per group) were then treated i.p. with LDE (200 mg/mL/kg body weight) or with vehicle alone (PBS) every 2 days for 19 days. Animals were observed twice daily and the body weight as well as the food consumption of each mouse was weighed every 2 days. LDE treatment did not alter the weight of mice, and the body weight and consumption of food in the LDE group were not noticeably different from that in the control group without LDE treatment (vehicle alone). Tumor size was measured every 2 days with calipers, based on the formula L 9 W 2 /2 where L is the length and W is the width of the tumor (Villares et al. 2008) . All mice were euthanized at day 19 after the injection of B16M cells following institutional regulation. After the mice had been killed, the solid tumor in each mouse was weighed.
Western blot analysis
This was performed according to the method published by Wang et al. (2009a, b) , Zhang et al. (2009), and Yu et al. (2009) . In brief, each tumor of the control group (n = 8) and LDE group (n = 8) were excised after the mice of both groups were killed. Equal amounts of protein lysates of each tumor were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with primary antibodies to mouse Bcl-2, Bax, and b-actin and then horseradish peroxidase-conjugated secondary antibodies, respectively. Anti-b-actin antibody was used as a loading control. Detection was done using an enhanced chemiluminescence system (GE Healthcare Life Sciences).
ELISAs for detection of protein levels of VEGF and HGF as well as OPN in tumors
This was performed according to the method published by Wang et al. (2009a, b) and Zhang et al. (2009) . In brief, each tumor in the control group (n = 8) and LDE group (n = 8) were excised after the mice of both groups were killed. Equal amounts of protein lysates of each tumor were analyzed by ELISA using kits for VEGF, HGF and OPN from R&D Systems (Minneapolis, MN.). ELISAs were done according to the instructions of the manufacturer. Each experiment was repeated three times.
Statistical analysis
Statistical analysis was done using the one-way or two-way ANOVA followed by the appropriate post hoc test (Bonferroni) and Student's t-test with the software SPPS 13.0. All statistical tests were twosided. Values between different treatment groups were compared. For confirming the synergistic effect between LDE and c-radiation treatment, comparison was made by two-way ANOVA followed by Bonferroni post hoc test. The relative cell viability (%), tumor volume, tumor weight, and the levels of VEGF, HGF and OPN are shown for each dose or each group; error bars indicate SD or SEM. Asterisk P \ 0.05, double asterisk P \ 0.01, and triple asterisk P \ 0.001. For all tests, P values less than 0.05 were considered statistically significant.
Results and discussion
In vitro suppression of growth in B16M cells by LDE and its effect on c-radiation treatment The in vitro growth assay showed that LDE suppressed the growth of B16M cells in dose-and time-dependent manners after the cells were treated with LDE at concentrations of 0.05-1.6 mg/mL for 24, 48 and 72 h, respectively. The IC50 values at 48 and 72 h were 1.0 and 0.9 mg/mL, respectively (Fig. 1a) . In addition, LDE at 0.4 mg/mL enhanced the effect on the reduction of the cell viability in B16M cells treated with c-radiation at the dose of 8 Gy (Fig. 1b) . The results suggest that LDE may not only have the potential to inhibit the B16M cell growth in vivo but also have a therapeutic and/or adjuvant therapeutic application in the treatment of human melanoma and other cancer.
LDE induced apoptosis by reducing the Bcl-2/Bax protein ratio in B16M cells
To understand the mechanisms of action of LDE against the growth in the B16M cells, we investigated the effects of LDE on apoptosis and expressions of Bcl-2/Bax proteins in the cells. Hoechst 33258 staining indicated that the typical morphological changes, such as formation of apoptotic bodies appeared in the B16M cells after the cells were treated for 48 h with LDE at 0.4 and 1.2 mg/mL, whereas the control cells without LDE treatment did not show the evident apoptotic morphological changes (Fig. 2a) . Furthermore, Western blot analysis confirmed that LDE dose-dependently downregulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein Bax, eventually leading to the reduction of the Bcl-2/Bax protein ratio in the B16M cells (Fig. 2b) . There have been studies showing that Bcl-2 and its dominant inhibitor Bax are key regulators of cell proliferation and apoptosis. Overexpression of Bcl-2 enhances cell survival by suppressing apoptosis, but overexpression of Bax accelerates cell death (Oltvai et al. 1993) . Induction of apoptosis and decrease in the ratio of Bcl-2/Bax proteins by LDE may be one of the important mechanisms of action of LDE against the B16M cell growth in vitro.
LDE suppressed tumor growth in melanomabearing mice and reduced the Bcl-2/Bax protein ratios in the tumors To determine whether or not LDE could suppress melanoma growth in vivo and reduce Bcl-2/Bax protein ratios in tumors, we conducted an animal experiment. The result of the animal experiment figure. The effects of LDE on the cell growth were determined by MTT assay as described in the ''Materials and methods'' section. b B16M cells were treated with c-radiation at dose of 8 Gy in the absence or presence of LDE at 0.4 mg/mL. After the treated cells were cultured for 48 h, the relative cell viability was determined using the trypan blue dye exclusion assay as described in the ''Materials and methods'' section. Each point and vertical bar represents the mean and SD for 6 wells. The figures (a, b) are the representative of three similar experiments performed. Statistical analysis was carried out using the ANOVA and Bonferroni test. All statistical tests were two-sided. Values with different letters (a-c) differ significantly (P \ 0.05)
showed that the incidence of tumors in mice was on the 7th day in the control group and on the 11th day in the LDE group. Compared with the control group, the tumor volume in mice was significantly and timedependently lower in LDE group (Fig. 3a) . The absolute weight of solid tumors in the LDE group was 7-fold lower than that in the control group (Fig. 3b) . Western blot analysis confirmed that compared with the control group, the Bcl-2 protein level in the tumors was lower and the Bax protein level in the tumors was high and thus the ratios of Bcl-2/Bax protein level in the tumors were lower in the LDE group (Fig. 4a, b) . These in vivo results further demonstrate that the reduction of Bcl-2/Bax protein ratios is one of molecular mechanisms of action of LDE suppressing the B16M cell growth in mice. These results partially explain why LDE has its therapeutic and/or adjuvant therapeutic effects on treatment for some cancer patients.
LDE reduced tumor progression-associated protein levels of VEGF, HGF, and OPN in melanoma-bearing mice To further understand the molecular mechanisms of action of LDE against the B16M cell growth in mice, section. The cells were treated for 48 h with LDE at the indicated concentrations; Anti-b-actin was used in Western blot analysis as a sample loading control. The ratio of Bcl-2 and Bax, (the ratio of relative density of each band normalized to b-actin), shown as mean ± SD (Bar) is relative to that of 0 (vehicle) as the control (designated as 100%). For one experiment, three assays were carried out and only one set of gels is shown. Statistical analysis was carried out using the ANOVA and Bonferroni test. * P \ 0.05. All statistical tests were two-sided. Values with different letters (a-e) differ significantly (P \ 0.05)
Cytotechnology (2010) 62:357-366 361 we investigated the effects of LDE on tumor protein levels of VEGF, HGF, and OPN in melanomabearing mice. The ELISA analysis indicated that compared with the control group, the tumor protein levels of VEGF, HGF, and OPN in melanomabearing mice were significantly lower in LDE group (Fig. 5a, b, c) . The tumor VEGF level decreased by an average of 1,052 ± 318 pg/mg, which represents a mean inhibition of 29.0% (Fig. 5a) . The tumor HGF level decreased by an average of 165 ± 52 pg/mg, which represents a mean inhibition of 36.6% (Fig. 5b) . The tumor OPN level decreased by an average of 672 ± 104 pg/mg, which represents a mean inhibition of 32.1% (Fig. 5c ). Increased protein levels of VEGF, HGF and OPN are associated with cancer cell growth, angiogenesis and metastasis (Kienast et al. 2010; Eder et al. 2009; McGill et al. 2006; Rangaswami and Kundu 2007; Rangel et al. 2008; Johnston et al. 2008; Philip et al. 2001) . VEGF is a key regulator of angiogenesis and VEGF expression correlates with tumor progression (Goh et al. 2007; Chen et al. 2009; Kienast et al. 2010) . Vascular endothelial growth factor-A (VEGF-A) /2 where L is the length and W is the width of the tumor. b After the mice had been killed, each tumor in mice was weighed as described in the ''Materials and methods'' section. Each value and bar represents the mean and SEM of eight mice in each group. **/*** Values are significantly different at P \ 0.01/P \ 0.001 by using the ANOVA and Student's t-test when compared to the control group Fig. 4 In vivo effects of LDE on the expressions of tumor Bcl-2/Bax proteins and reduction of Bcl-2/Bax ratio in melanomabearing mice. After the mice in the control group (n = 8) and LDE group (n = 8) were killed, each tumor in both groups was excised. The expressions of Bcl-2 and Bax proteins in each tumor were analyzed by Western blotting as described in ''Materials and methods'' section. Anti-b-actin was used in Western blot analyses as a sample loading control. In (a) and (b), C1, C2, C3, C4, C5, C6, C7 and C8 are the analyzed samples, respectively from the tumors of each mouse in the PBS-treated control group; LDE1, LDE2, LDE3, LDE4, LDE5, LDE6, LDE7 and LDE8 are the analyzed samples, respectively from the tumors of each mouse in the LDE-treated group. Compared with the PBS-treated control group, each sample in the LDE-treated group shows significantly lower ratio of Bcl-2 and Bax protein levels. The ratio (%) of Bcl-2 and Bax, (the ratio of relative density of each band normalized to b-actin), shown as mean ± SD (Bar) is relative to that of C1 in (a) or C5 in (b) as the control (designated as 100%). For one experiment, three assays were carried out and only one set of gels is shown. Statistical analysis was carried out using the ANOVA and Student's t-test. Values with different letters (a-b) differ significantly (P \ 0.05) inhibition induced long-term dormancy of lung cancer micrometastases by preventing angiogenic growth to macrometastases. VEGF becomes the important target of therapies (Kienast et al. 2010; Chen et al. 2009; Kerr 2004) . Inappropriate c-Met signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors, contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. The c-Met ligand, HGF/SF participates in all stages of malignant progression and represents a promising drug targets in a variety of cancer types, including melanoma (Eder et al. 2009; McGill et al. 2006) . OPN is a glycophosphoprotein cytokine associated with the growth and metastasis of various cancer cells including melanoma cells (Johnston et al. 2008; Rangaswami and Kundu 2007; Rangel et al. 2008) . In the present study, the suppression of VEGF, HGF and OPN in B16M tumor by LDE may be related to inhibition of phosphatidylinositol 3 0 -kinase (PI3 K)/Akt (protein kinase B) and nuclear factor-jB (NF-jB) signaling pathway. There have been studies showing that OPN stimulated tumor growth and activated NF-jB signaling pathway in melanoma cells (Rangaswami et al. 2004) ; OPN induced PI3K dependent Akt phosphorylation and NF-jB activity (Das et al. 2003 (Das et al. , 2005 in cancer cells; overexpression of Akt led to upregulation of VEGF and rapidly growing melanomas in vivo (Govindarajan et al. 2007) ; the activation of PI3K/Akt pathway induced by the HGF/c-Met axis was involved in promoting the enhanced motility and migration of uveal melanoma cells (Ye et al. 2008) ; HGF/c-Metactivated PI3K/Akt signaling pathway was important for melanoma cell survival (Carlson et al. 2007 ); activation of NF-jB signaling pathway led to upregulation of VEGF and HGF in cancer cells (Xie et al. 2010; Fan et al. 2005; Maroni et al. 2007 ). Inhibition of NF-jB activity decreased the VEGF mRNA expression in cancer cells (Shibata et al. 2002) . Our previous results also confirmed that the inhibition of PI3K/Akt and NF-jB signaling pathway and reduction of expressions of VEGF and OPN were associated with decrease in cell viability in cancer cells (Wang et al. 2009a, b; Yu et al. 2009 ).
NF-jB is a nuclear transcription regulator with a specific motif for Bcl-2 transcription (Viatour et al. 2003; Wei et al. 2001; Marsden et al. 2002) . The PI3K/Akt pathway acts as a survival (anti-apoptotic) signal and plays a key role in the regulation of apoptotic change in cancer cells. Akt can exert its anti-apoptotic effects in several different ways, such as negatively regulating pro-apoptotic factors, stimulating the NF-jB survival pathway (Sizemore et al. 1999; Ozes et al. 1999; Mayo and Donner 2002; Nicholson and Anderson 2002) . Activation of p-Akt and the NF-jB/Bcl-2 pathway leads to inhibition of chemotherapy-induced apoptosis, which results in Fig. 5 In vivo effects of LDE on the expressions of tumor VEGF, HGF, and OPN proteins in melanoma-bearing mice. After the mice in the control group (n = 8) and LDE group (n = 8) were killed, each tumor in both the groups were excised. The expressions of VEGF, HGF, and OPN proteins was in each tumor were analyzed by ELISA as described in ''Materials and methods'' section. Each point and vertical bar represents the mean and SD for six wells. The figures (a, b, and c) are the representatives of three similar experiments performed. Statistical analysis was carried out using the ANOVA and Bonferroni test. All statistical tests were twosided. ** P \ 0.01, *** P \ 0.001 treatment resistance (Wang et al. 1996) . The Bax, Bcl-2, p-Akt and NF-jB have become the important targets of action by anticancer agents (Wang et al. 1996; Marsden et al. 2002; Patel et al. 2007; Gupta et al. 2002; Emi et al. 2005; Aggarwal 2004 ). There has been a report that 17-acetoxyjolkinolide B (17-AJB), one of the LDE constituents induced apoptosis of hepatoma cells, which was associated with the inhibition of NF-jB pathway and NF-jB-regulated genes such as Bcl-2, BAX-a, etc. (Yan et al. 2008 ). Our present results have shown that LDE inhibited the B16M cell growth, induced apoptosis and reduced the Bcl-2/Bax protein ratio in cancer cells. We also found that LY294002, the inhibitor of PI3K/Akt, and Bay 11-7082, the inhibitor of NF-jB induced cell viability and the Bcl-2/Bax protein ratio in B16M cells (data not shown). These results suggest that the inhibitory effects of LDE on cell growth and Bcl-2/ Bax protein ratio may be relevant to the inhibition of PI3K/Akt and NF-jB pathway, and its upstream and/ or downstream targets such as OPN, HGF and VEGF although LDE may not directly target these factors. It should be noted that LDE may have no or low toxic effect on normal cells because the results from both the present animal experiment and our ongoing clinical experiment have not shown evident toxic effects on LDE-treated mice and patients who received LDE treatment.
In the present study, we have demonstrated that LDE inhibits the B16M cell growth and reduces the Bcl-2/Bax protein ratios not only in vitro but also in vivo in mice. Induction of apoptosis and downregulation of Bcl-2/Bax protein ratios as well as reduction of the protein levels of VEGF, HGF and OPN may be the important mechanisms of action of LDE against the B16M cell growth. There has been no report to show the inhibitory effects of LDE or a compound in LDE on tumor growth in melanomabearing mice as yet. This is the first time for us to report here that LDE suppresses melanoma growth in vivo, reduces tumor Bcl-2/Bax protein ratios as well as decreases the tumor protein levels of VEGF, HGF, and OPN in the melanoma-bearing mice. There have been studies showing that the compounds such as jolkinolide A, 17-AJB, jolkinolide B, fischeriana A, and fischeriana B in LDE inhibited the in vitro cell growth of some cancer lines such as human leukemia K562, hepatoma HepG2 (Luo and Wang 2006; Wang et al. 2009a, b; Yan et al. 2008 ) and/or human prostate LNCaP cancer cells (Liu et al. 2002) . Our present results suggest that the synergistic effects of jolkinolide (A, B) and fischeriana (A, B) as well as some unidentified compounds in LDE may be responsible for the suppression of both in vitro and in vivo growth of the B16M cells as well as the tumor protein expressions of Bcl-2/Bax, VEGF, HGF, and OPN in melanoma-bearing mice. Our present results also suggest that LDE may have the therapeutic and/ or adjuvant therapeutic application in the treatment of human melanoma and other cancer. The related clinic investigation of the LDE therapeutic and adjuvant therapeutic effects on cancer patients is ongoing in the PLA 107 hospital in China.
